Tacrolimus의 혈중농도측정법 비교 및 간이식환자에서의 집단 약동학
Comparison of Analytical Methods of Tacrolimus in Plasma and Population Pharmacokinetics in Liver Transplant Recipients
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
This study aimed to compare a microparticle enzyme immunoassay (MEIA) with a liquid chromatography-tandem mass spectrometry (LC/MS/MS) technique for the measurement of tacrolimus concentrations in adult liver transplant recipients, to investigate how the assay choice influenced the population pharmacokinetics of tacrolimus and to identify patient characteristics that affected pharmacokinetic parameters in each assay. Tacrolimus concentrations from 29 liver (n=52 paired-samples) transplant recipients measured by both MEIA and LC/MS/MS were used to evaluate the performance of these methods in the clinical setting. Tacrolimus pharmacokinetics was studied independently using MEIA and LC/MS/MS data in 70 adult patients using a population approach performed with NONMEM. Patient characteristics which influenced pharmacokinetic parameters in each assay were compared. The relation between LC/MS/MS and MEIA measurements was best described by the regression equation MEIA=1.465*LC/MS/MS- 1.336 (r=0.91). Multiple linear regression analysis showed significant inverse relationships between assay difference and hematocrit (Hct) (p<0.025) in liver graft recipients. In MEIA, the population estimate of tacrolimus CL/F and apparent volume of distribution (Vd/F) were found to be 10.1 L/h and 226 L, and in LC/MS/MS, 13 L/h and 305 L respectively. Neither patient's age, weight, gender, grafted hepatic weight, albumin concentration, nor markers of liver function influenced tacrolimus CL/F. The final model of CL/F was found to be 10.1+(Hct/Hct mean)12.0 in MEIA and 13+(1+Hct/578) in LC/MS/MS indicating that CL/F was influenced by hematocrit.
Abstract
This study aimed to compare a microparticle enzyme immunoassay (MEIA) with a liquid chromatography-tandem mass spectrometry (LC/MS/MS) technique for the measurement of tacrolimus concentrations in adult liver transplant recipients, to investigate how the assay choice influenced the population pharmacokinetics of tacrolimus and to identify patient characteristics that affected pharmacokinetic parameters in each assay. Tacrolimus concentrations from 29 liver (n=52 paired-samples) transplant recipients measured by both MEIA and LC/MS/MS were used to evaluate the performance of these methods in the clinical setting. Tacrolimus pharmacokinetics was studied independently using MEIA and LC/MS/MS data in 70 adult patients using a population approach performed with NONMEM. Patient characteristics which influenced pharmacokinetic parameters in each assay were compared. The relation between LC/MS/MS and MEIA measurements was best described by the regression equation MEIA=1.465*LC/MS/MS- 1.336 (r=0.91). Multiple linear regression analysis showed significant inverse relationships between assay difference and hematocrit (Hct) (p<0.025) in liver graft recipients. In MEIA, the population estimate of tacrolimus CL/F and apparent volume of distribution (Vd/F) were found to be 10.1 L/h and 226 L, and in LC/MS/MS, 13 L/h and 305 L respectively. Neither patient's age, weight, gender, grafted hepatic weight, albumin concentration, nor markers of liver function influenced tacrolimus CL/F. The final model of CL/F was found to be 10.1+(Hct/Hct mean)12.0 in MEIA and 13+(1+Hct/578) in LC/MS/MS indicating that CL/F was influenced by hematocrit.
참고문헌 (28)
- Shapiro R, "Tacrolimus in solid organ transplantation: an update", Transplant Proc, 31, pp.2203~2205 (1999)
- Anon, "The European FK 506 Multicentre Psoriasis Study Group: Systemic tacrolimus (FK 506) is effective for the treatment of psoriasis in a double-blind, placebo-controlled study", Arch Dermatol, 132, pp.419~423 (1996)
- Tzakis AG, "Use of FK 506 in pediatric patients", Transplant Proc, 23, pp.924~927 (1991)
- Glanemann M, "Mycophenolate mofetil is superior in combination with tacrolimus compared to cyclosporine for immunosuppressive therapy after liver transplantation", Transplant Proc, 33, pp.1069~1070 (2001)
- Jusko WJ, "Consensus document : therapeutic monitoring of tacrolimus (FK-506)", Ther Drug Monit, 17, pp.606~614 (1995)
- Backman L, "FK506 trough levels in whole blood and plasma in liver transplant recipients. Correlation with clinical events and side effects", Transplantation, 57, pp.519~525 (1994)
- Venkataramanan R, "Clinical utility of monitoring tacrolimus blood concentrations in liver transplant patients", J Clin Pharmacol, 41, pp.542~551 (2001)
- Venkataramanan R, "Clinical pharmacokinetics of tacrolimus", Clin Pharmacokinet, 29(6), pp.404~430 (1995)
- Jusko WJ, "Analysis of tacrolimus (FK 506) in relation to therapeutic drug monitoring", Ther Drug Monit, 17, pp.596~601 (1995)
- Taylor PJ, "Therapeutic drug monitoring of tacrolimus (FK506) using tandem mass spectrometry", Ther Drug, 20, pp.240~241 (1998)
- Zhang Q, "A specific method for the measurement of tacrolimus in human whole blood by liquid chromatography", tandem mass spectrometry, 1997, pp.19, 470~476
- Volosov A, "Simultaneous simple and fast quantification of three major immunosuppressants by liquid chromatography-tandem mass-spectrometry", Clin Biochem, 34, pp.285~290 (2001)
- Brown NW, "Low hematocrit and serum albumin concentrations underlie the overestimation of tacrolimus concentrations by microparticle enzyme immunoassay versus liquid chromatography-tendem mass spectrometry", Clin Chem, 51, pp.586~592 (2005)
- Gonschior AK, "Simplified high-performance liquid chromatography-mass spectrometry assay for measurement of tacrolimus and its metabolites and cross-validation with microparticle enzyme immunoassay", Ther Drug Monit, 17(5), pp.504~510 (1995)
- Kuzuya T, "Interference of hematocrit in the tacrolimus II microparticle enzyme immunoassay", Ther Drug Monit, 24, pp.507~511 (2002)
- Homma M, "False positive blood tacrolimus concentration in microparticle enzyme immunoassay", Biol Pharm Bull, 25, pp.1119~1120 (2002)
- Taylor PJ, "Tacrolimus measurement by microparticle enzyme immunoassay II", Ther Drug Monit, 25, pp.259~260 (2003)
- Chow FS, "Effect of hematocrit and albumin concentration on hepatic clearance of tacrolimus (FK506) during rabbit liver perfusion", Drug Metab Dispos, 25, pp.610~616 (1997)
- Spencer CM, "Tacrolimus: an update of its pharmacology and clinical efficacy in the management of organ transplantation", Drugs, 54, pp.925~975 (1997)
- Piekoszewski W, "Plasma protein binding of tacrolimus in humans", J Pharm Sci, 82, pp.340~341 (1993)
- Iwasaki K, "Further metabolism of FK506 (tacrolimus): identification and biological activities of the metabolites oxidized at multiple sites of FK506", Drug Metab Dispos, 23, pp.28~34 (1995)
- Tamura K, "Interaction of tacrolimus (FK506) and its metabolites with FKBP and calcineurin", Biochem Biophys Res Commun, 202, pp.437~443 (1994)
- Braun F, "Clinical relevance of monitoring tacrolimus: comparison of microparticle enzyme immunoassay, enzyme-linked immunosorbent assay, and liquid chromatography mass spectrometry in renal transplant recipients converted from cyclosporine to tacrolimus", Transplant Proc, 28, pp.3175~3176 (1996)
- Zahir H, "Population Pharmacokinetic Estimation of Tacrolimus Apparent Clearance in Adult Liver Transplant Recipients", Ther Drug Monit, 7, pp.422~430 (2005)
- Staatz CE, "Population pharmacokinetics of tacrolimus in adult kidney transplant recipients", Clin Pharmacol Ther, 72, pp.660~669 (2002)
- Zahir H, "Factors affecting variability in distribution of tacrolimus in liver transplant recipients", Br J Clin Pharmacol, 57, pp.298~309 (2004)
- Floren LC, "Tacrolimus oral bioavailability doubles with coadministration of ketoconazole", Clin Pharmacol Ther, 62, pp.41~49 (1997)
- Tuteja S, "The effect of gut metabolism on tacrolimus bioavailability in renal transplant recipients", Transplantation, 71, pp.1303~1307 (2001)